B. Riley Has Positive Estimate for ARWR Q3 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) – Equities research analysts at B. Riley lifted their Q3 2025 EPS estimates for shares of Arrowhead Pharmaceuticals in a research report issued to clients and investors on Tuesday, May 13th. B. Riley analyst M. Mamtani now forecasts that the biotechnology company will post earnings per share of […]

Leave a Reply

Your email address will not be published.

Previous post Q3 EPS Estimate for Intuitive Machines Raised by Analyst
Next post Baird Financial Group Inc. Makes New Investment in iShares Convertible Bond ETF (BATS:ICVT)